Part five of seven: Krishna Shah, Gastroenterology Registrar and IBD Research Fellow at the Royal London Hospital and Dr. Kamal Patel, Consultant Gastroenterologist at St George's Hospital discuss the Advanced Therapies in Ulcerative Colitis section of the new BSG guidelines beginning with mesalazine, prednisolone and azathioprine through to thiopurines and anti-TNFs. They discuss the cost-benefit outcomes of the drug pathways advised in the BSG Guidelines including some of the potential adverse side-effects.